Citations

Mayo Clinic

Clear

15414 citation(s) found for "Iv, Michael".

Pancreas Transplantation for Recipients with Type 2 Diabetes Mellitus: Results of an International Survey
Fridell, Jonathan A. , Uva, Pablo D., Kukla, Aleksandra, Delonais‐Parker, Ava , Mansuri, Rushda Faruk, Axelrod, David, Dunn, Ty, Niederhaus, Silke V. , Parsons, Ronald, Pleass, Henry, Paraskevas, Steven , Rickels, Michael R., Stratta, Robert J., Ventura-Aguiar, Pedro, Fridell, Jonathan A. , Uva, Pablo Daniel , Kukla, Aleksandra , Axelrod, David A. , Dunn, Ty B , Parsons, Ronald F. , Pleass, Henry C. C. , Rickels, Michael R. , Stratta, Robert J. , Ventura‐Aguiar, Pedro , Woodside, Kenneth J. , Lentine, Krista L.

Transplantation Direct | June 7, 2026 | Volume: 12 | Issue: 7 | Pages: e1963

10.1097/txd.0000000000001963 | PMID 42256091 Get It

Background. Pancreas transplantation (PT), historically limited to patients with type 1 diabetes (T1D), is currently performed successfully in selected patients with type 2 diabetes (T2D). However, contemporary practice patterns and eligibility criteria for PT in T2D remain incompletely characterized. Methods. The International Pancreas and Islet Transplant Association Pancreas Transplant Interest Group developed an electronic survey to assess center-level approaches to patient phenotyping, candidacy, and peri- and posttransplant management for PT in patients with T2D. The survey was distributed to international transplant professionals during an International Pancreas and Islet Transplant Association Pre-Congress meeting on June 15, 2025. Results. Thirty-seven participants completed the survey. Most respondents’ programs offer PT for T2D only when a kidney transplant is also indicated. Fewer respondents’ programs also offer PT alone (10%), evaluate T2D candidates on a case-by-case basis (3%), or do not offer PT to patients with T2D (10%). Total daily insulin requirement and body mass index (BMI) were the most selected factors in determining eligibility. Considerable variability existed in metabolic thresholds: 62% of programs reported no C-peptide cutoff, whereas nearly half required a BMI of <30 kg/m 2 for C-peptide-positive candidates. Respondents frequently recommend weight-optimization strategies, including lifestyle modification, glucagon-like peptide-1 receptor agonists, and bariatric surgery for candidates exceeding acceptable BMI thresholds. Surgical technique, induction, and maintenance immunosuppression and early posttransplant glycemic management were largely uniform between T2D and T1D recipients. Conclusions. International practice reflects broad but heterogeneous adoption of PT for T2D, with most participants restricting its use to candidates requiring kidney transplantation and emphasizing integrated clinical phenotyping approaches.
Defining rapid early progression in glioblastoma—A volumetric approach
Munlapudi, Vikram , Guzzino, Jacob , Crompton, David J., Agarwal, Shubhi , Lehrer, Eric J. , Kern, Shelby, Bogan, A.W., Vora, Sujay A., Quinones-Hinojosa, Alfredo, Sherman, Wendy J, Brown, P D, Laack, Nadia, Peterson, Jennifer, Uhm, Joon H, Ruff, Michael W. , Breen, William G. , Trifiletti, Daniel M. , Quinones-Hinojosa, Alfredo , Sener, Ugur T, Breen, Will , Trifiletti, Daniel M , Quiñones‐Hinojosa, Alfredo , Burns, Terry C. , Sherman, Wendy, Uhm, Joon H. , Sener, Uğur

Neuro-Oncology Advances | June 6, 2026 | Volume: 8 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdag153 | PMID 42382820 Get It

Abstract Background The current treatment of glioblastoma involves resection followed by radiotherapy (RT) and temozolomide. Rapid early progression (REP) of tumor in the surgery-to-radiotherapy interval (SRI) has been described using categorical or semi-quantitative assessments and is associated with inferior clinical outcomes. This study seeks to establish and validate a quantitative definition for REP and examine how REP could inform future therapy. Methods Volumes of tumor and resection cavity at 3 time points—preoperative, postoperative and RT-planning (pre-RT)—were contoured among patients who had undergone standard of care. A minimal, but clinically appreciable, threshold for defining REP based on change in tumor volume was established, validated, and subsequently used to assess actionable predictors of REP and its prognostic value. Results An increase of &gt;2 cc in volume or a new satellite tumor between the post-operative to planning MRI was found to be a sensitive, pragmatic, and statistically significant cutoff for REP (P = .002). Actionable predictors such as SRI of 6 weeks and a &gt; 5 cc residual immediate post-operative tumor volume were found to be statistically significant predictors of REP. REP was also found to be a statistically significant prognostic indicator for overall survival (P = .002) and progression-free survival. Conclusion These findings support that an increase in tumor volume between post-operative and pre-RT MRI of &gt;2 cc is the ideal working definition of REP in this clinical setting. Furthermore, REP could serve as a prognostic ­biomarker to track treatment response. Additionally, 2 actionable predictors of REP, post-op residual tumor volume and SRI, are identified.
Cardiac magnetic resonance imaging parameters predict new-onset symptoms of heart failure in hypertrophic cardiomyopathy
Silva, Danuzia Santana da, Vizentin, Vanessa Karlinski , Maanja, Maren , Lahori, Simmy A, Ommen, Steve, Geske, Jeffrey B, Giudicessi, John R, Araoz, Philip A. , Ackerman, Michael J, Arruda‐Olson, Adelaide M. , Bos, J. Martijn , da Silva, Danuzia S, Félix, Iuri Ferreira , Bos, Johan M , Lahori, Simmy , Pasupathy, Kalyan S. , Ommen, Steve R. , Geske, Jeffrey B. , Giudicessi, John R. , Ackerman, Michael J.

ESC Heart Failure | June 6, 2026 | Volume: 13 | Issue: 3 | Pages: No page available

10.1093/eschf/xvag160 | PMID 42263198 Get It

Abstract Background Hypertrophic cardiomyopathy (HCM) is a heritable cardiac disorder characterized by increased left ventricular (LV) wall thickness, often leading to heart failure (HF). The role of cardiovascular magnetic resonance (CMR) imaging in predicting new onset of HF symptoms in patients with HCM remains unknown. This study aimed to identify CMR predictors of new-onset HF symptoms in individuals with HCM. Methods This study was a single-centre retrospective cohort study of HCM patients treated at a tertiary referral centre in the USA who underwent CMR examination between 1998 and 2018, had no HF symptoms at baseline CMR, and at least 1 year of follow-up. Clinical data were collected by review of electronic medical records, and CMR images were analyzed by a blinded expert cardiac radiologis. The primary outcome was new onset of HF symptoms, defined as New York Heart Association (NYHA) class ≥ II at follow-up. Kaplan–Meier analyses and Cox proportional hazard analyses were performed. Results Of 1462 patients diagnosed with HCM who had at least 1 CMR, 276 HCM patients without HF symptoms (average age 52.7 years, 33.3% female),median maximum left ventricular (LV) wall thickness was 19 mm ([IQR] 17–22) with a and median LV ejection fraction of 71% (IQR 66–77). Late gadolinium enhancement was detected in 56.2%) patients (60.7% had mild; 30.7% moderate; 8.6% severe). During a median follow-up period of 6.3 years, 93 patients developed HF symptoms (NYHA class II in 56 (60.2%); class III in 31 (33.3%); and class IV in 6 (6.5%). Multivariable analysis adjusted for age showed that LA enlargement (HR 1.626; 95% CI 1.01–2.62; P = .045) and LV mass index (HR 1.014; 95% CI 1.007–1.022; P≤ .001) and sex (HR 1.7; 95% CI 1.074–2.691; P = .023) were independent predictors of new onset of HF symptoms in patients with HCM. Conclusions Nearly half of the patients with HCM developed HF symptoms within 6.3 years. Left atrial enlargement, LV mass index, and sex were independent predictors of new onset of HF symptoms in HCM patients. These findings emphasize the value of CMR in HF risk stratification.
Temporary Vascular Shunting to Prevent Excessive Ischemia Time for a Fillet‐of‐Leg Free Flap During External Hemipelvectomy: A Case Report
Edgar, Michael , Pourriyahi, Homa , Zeid, Naji Bou , Wisselink, Willem , Alkureishi, Lee , Bou Zeid, Naji , Alkureishi, Lee W. T.

Microsurgery | June 6, 2026 | Volume: 46 | Issue: 5 | Pages: No page available

10.1002/micr.70254 | PMID 42249727 Get It

ABSTRACT The free fillet flap is a well‐established reconstructive option following external hemipelvectomy. However, mitigating prolonged warm ischemia during the extensive tumor resection poses a significant challenge to flap viability. Presented herein is a case illustrating the novel use of temporary intraoperative vascular shunting to overcome this limitation. During hemipelvectomy for a 17.7 × 16.9 × 19.3 cm osteosarcoma of the proximal left femur in a 74‐year‐old man, unplanned early ischemia of the lower extremity was addressed by placing carotid shunts between the external iliac and popliteal vessels. The technique maintained continuous perfusion to the future flap for 4 h during the concurrent pelvic resection and fillet flap harvest. Definitive microvascular anastomosis was performed subsequently and the 37 × 31 cm flap remained viable postoperatively for the 3 months of follow‐up. This case report reintroduces temporary shunting as a simple, effective, and readily available technique to preserve flap perfusion in complex microsurgical reconstructions, mirroring damage‐control principles from trauma surgery.
Safety of esophageal endoscopic submucosal dissection of Barrett’s esophageal neoplasia: an analysis of factors associated with stricture formation
Omae, M, Isacsson, N Hentati, Maltzman, H, Mathieu, P, Moll, F, Bourke, M J, Gupta, S, Ebigbo, A, Roser, D A, Deprez, P, Maximilien, B, Wang, K K, Leggett, C L, Koch, A D, Maan, AD I, Baldaque-Silva, F, Omae, Masami , Isacsson, Nils Hentati , Maltzman, Henrik , Moll, Frederic C., Bourke, Michael J. , Ebigbo, Alanna , Barret, Maximilien , Leggett, Cadman L. , Baldaque‐Silva, Francisco

Endoscopy | June 5, 2026 | Volume: 58 | Issue: S 03 | Pages: S107-S108

10.1055/s-0046-1820814 Get It

BRAF-altered glioma in adults and children: A Society for Neuro-Oncology (SNO) and European Society for Neuro-Oncology (EANO) consensus review on clinical management and future directions
Schreck, Karisa C, Fuente, Macarena I de la, Fat, Mary Jane Lim, Maas, S L, Levy, Jean M Mulcahy, Lombardi, G , Perrault, Sébastien, Petritsch, Claudia , Aldape, Kenneth, Chang, Susan M, Holdhoff, Matthias, Kazda, Tomas, Rhun, Emilie Le, Minniti, Giuseppe, Mueller, Sabine, Preusser, M, Smits, Marion, Weller, Michael, Wen, Patrick Y, Bent, Martin van den, Geurts, Marjolein, Lombardi, Giuseppe , Maas, Sybren L. N. , Schreck, Karisa C. , Levy, Jean M. Mulcahy , Chang, Susan M. , Duerinck, Johnny , Holdhoff, Matthias , Kazda, Tomáš , Rhun, Émilie Le , Minniti, Giuseppe , Mishra, Mark V. , Mueller, Sabine , Padovan, Marta , Preusser, Matthias , Smits, Marion , Weller, Michael , Bent, Martin J. van den , Geurts, Marjolein

Neuro-Oncology | June 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/neuonc/noag135 | PMID 42261252 Get It

Abstract Oncogenic BRAF alterations occur in a subset of diffuse gliomas across WHO grades and are increasingly identified through modern molecular diagnostics. In addition to standard glioma therapies, targeted treatments are available for patients with BRAF-altered glioma supported by variable evidence spanning randomized trials, single-arm studies, and real-world evidence. This joint consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO) synthesizes current knowledge on the diagnosis and management of BRAF-altered gliomas across age groups, tumor grades, and lines of therapy. Particular emphasis is placed on expert consensus in clinical scenarios where high-quality trial evidence remains limited. The review addresses rationale testing for BRAF alterations, selection, and monitoring of targeted therapies, management of treatment-related toxicities, approaches to resistance, and priorities for future research. It aims to provide practical, evidence-based guidance for clinicians while highlighting gaps to inform prospective studies.
The effect of rocking speed and cell inoculation density on hepatic spheroid size: A simple method for size modulation
Megaly, Michael , Tobolt, Diane, Chen, A. W. , Namsrai, Bat‐Erdene, Fisher, Benjamin , Ramesh, Srivasupradha, Chimedtseren, Anudari, Nyberg, Scott L. , Clemens, Dr Mark, Lee, Charles Y., Finger, Erik B. , Tobolt, Diane, Rao, Joseph Sushil , Ramesh, Srivasupradha, Bischof, John C , Finger, Erik B.

Bioengineering & Translational Medicine | June 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/btm2.70154 Get It

Abstract Hepatic spheroids are widely used in bioartificial liver (BAL) systems, hepatotoxicology, and pharmacology due to improved functional stability compared with monolayer cultures. However, many existing methods rely on specialized equipment or static platforms that limit scalability and dynamic culture applications. Primary rat hepatocytes were cultured as three‐dimensional spheroids using a rocker‐based suspension system. Spheroid formation was evaluated across a range of rocking speeds (7–18 cycles per minute [cpm]) and inoculation densities. Spheroid morphology was quantified over time using two‐dimensional imaging. Functional performance was assessed by urea and albumin production on days 1, 4, 7, and 10. Spheroid formation efficiency was evaluated using volumetric modeling. Mean spheroid diameter decreased from 199 ± 41 μm at 7 cpm to 80.2 ± 17.6 μm at 18 cpm. The spheroid area was significantly influenced by both culture day ( p < 0.0001) and rocker speed, with significant differences observed across speeds at all time points ( p < 0.001, days 1–7). Mean spheroid area at 10 cpm was 13,750 ± 9051 μm 2 (day 1), 26,730 ± 8658 μm 2 (day 4), and decreased to 22,526 ± 8705 μm 2 (day 7). Urea production differed across speeds (ANOVA, p = 0.043), with peak performance at 12 cpm (median 3.47 μg/μg DNA) compared to 7 cpm (median 0.11 μg/μg DNA). Albumin production was 1086.8 ng/μg DNA on day 1 and 1534.4 ng/μg DNA on day 10. Urea production was 0.62 μg/μg DNA on day 1 and 1.25 μg/μg DNA on day 10. Median hepatocyte incorporation was 86% (range 73%–116%) by day 4. This rocker‐based method provides a simple, low‐cost, and scalable approach for generating hepatic spheroids with tunable size distributions under dynamic conditions. The system supports progressive functional maturation and is compatible with established scale‐up strategies, supporting its potential for translational applications.
Femoral Nerve Block: A Review of the Relevant Applied Anatomy, Anatomical Variations, and Procedural Considerations
Dai, Yuqian, MD, Montalbano, Michael J.,, Marshall, Ewarld, Loukas, Marios , Montalbano, Michael J. , Montalbano, Michael J , Dai, Yuqian , Marshall, Ewarld

Clinical Anatomy | June 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ca.70152 | PMID 42244330 Get It

ABSTRACT Femoral nerve block is an essential regional anesthetic technique for surgery and analgesia of the anterior thigh, hip, and knee. Its effectiveness depends on understanding the femoral nerve's origin, branching pattern, fascial relationships, and common anatomical variations. This review summarizes current anatomical, cadaveric, and imaging studies to clarify the course of the femoral nerve and highlight variations such as high divisions, accessory branches, and vascular overlap that may influence block success. Approaches including landmark, nerve stimulator, and ultrasound‐guided techniques are reviewed with emphasis on procedural anatomy. Ultrasound features of the femoral nerve and fascia iliaca are correlated with cadaveric findings to outline optimal needle placement and spread of injectate. Continuous catheter methods, anesthetic selection, and volume considerations are also described. Comparative evidence indicates that ultrasound guidance improves accuracy, reduces vascular puncture, and decreases local anesthetic requirements compared with blind or stimulator‐based approaches. Clinical applications across orthopedic surgery, trauma care, and multimodal perioperative pathways are discussed, along with potential complications such as nerve injury, hematoma, systemic toxicity, and quadriceps weakness. Specifically, detailed knowledge of the femoral nerve's course beneath the fascia iliaca, its shifting proximity to the femoral vessels, and its variable early branching is the key to accurate needle placement, dependable block success, and fewer procedure‐related complications.
Healthcare Education Pathway Pilot Programs May Advance Institutional Diversity Efforts
Elkhatib, Wiaam, Fernandez, Valerie, Alcindor, Sarah E., Boniface, Michael, Dinkins, Maryane, Ladlie, Beth, Ausejo, David, Austin, Andrew, Elkhatib, Wiaam Y , Elkhatib, Wiaam , Boniface, Michael , Dinkins, Maryane, Ladlie, Beth L., Austin, Andrew

Journal of Allied Health | June 5, 2026 | Volume: 55 | Issue: 2 | Pages: 375-383

10.21091/jah.2026.02044 | PMID 42246748 Get It

Racial minorities remain underrepresented among allied health providers. Pathway programs address this gap by fostering career exposure and mentorship for underrepresented students. A pilot program was designed to increase underrepresented minority (URM) students entering health professions through career exploration and mentorship. High school students were enrolled into a pre-post survey study through a healthcare magnet school having higher proportions of economically disadvantaged students. Career exploration included healthcare presentations and skills sessions. Students were matched with mentors based on career interests. 22 students participated. The program facilitated career exploration sessions, mentor-mentee meetings, and workshops with diverse healthcare professionals. Participants reported increased likelihood towards pursuing healthcare careers. Preliminary findings suggest similar pilot pathway programs may increase URM student interest in healthcare careers.